(-)-Terreic acid (Synonyms: TA, (-)-Terreic Acid) |
| Catalog No.GC12164 |
Bruton's tyrosine kinase (BTK) inhibitor
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 121-40-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
IC50: about 100 μM for binding of GST-BtkPH to PKC, about 30 μM for association of Btk with PKCbII, about 10 μM for JNK1 activity, and about 7 μM for TNF-a and about 3 μM for IL-2.
Terreic acid (TA), which was known as Aspergillus sp. No. Y-8980, was isolated from a soil sample abtained at Yoron Island of Kagoshima Prefecture.
Terreic acid is a quinone epoxide with antibiotic activity. At a mechanism view for its antibiotic action, it inhibits protein synthesis by blocking the formation of leucyl-tRNA in sensitive bacteria [1]. TA was also an inhibitor of Bruton’s tyrosine kinase (Btk) that blocks the PKC-Btk PH domain interaction. Btk plays core roles in mast cell activation and in B cell development [2].
In vitro: Terreic acid showed MIC (minimal inhibitory concentration) of 25 approximately 100 mcg/ml, 50 mcg/ml and 12.5 mcg/ml against Gram-positive and Gram-negative bacteria, Xanthomonas citri and Xanthomonas oryzae and, respectively. TA also showed anti-tumor effect in the concentrations of > 6.25 mcg/ml on human carcinoma cells (HeLa cells) [1]. In lysates of HMC-1 human mast cells, TA can inhibit the binding of GST-BtkPH to PKC with an IC50 of ~100 uM. In mouse mast cells, TA can inhibit the association of Btk with PKCbII at IC50 of ~ 30 uM. JNK1 activity can be inhibited by TA with an IC50 of ~10 uM. Cytokine secretion was severely impaired by TA with an IC50 of ~7 uM for TNF-a and ~ 3 uM for IL-2) [2].
In vivo: In mice, the LD50 (median lethal dose) of TA was 75 mg/kg through i.p. and i.v. TA showed the enough survival effect in dd mice which have been implanted with Ehrlich ascites carcinoma cells, and the effect also was confirmed by anatomies of mice [1].
Clinical trial: So far, no clinical study has been conducted.
References:
[1] Yamamoto H, Moriyama K, Jinnouchi H, Yagishita K. Studies on terreic acid. Jpn J Antibiot. 1980 Mar;33(3):320-8.
[2] Kawakami Y, Hartman SE, Kinoshita E, Suzuki H, Kitaura J, Yao L, Inagaki N, Franco A, Hata D, Maeda-Yamamoto M, Fukamachi H, Nagai H, Kawakami T. Terreic acid, a quinone epoxide inhibitor of Bruton's tyrosine kinase. Proc Natl Acad Sci U S A. 1999 Mar 2;96(5):2227-32.
| Cas No. | 121-40-4 | SDF | |
| Synonyms | TA, (-)-Terreic Acid | ||
| Chemical Name | (1S,6R)-3-hydroxy-4-methyl-7-oxabicyclo[4.1.0]hept-3-ene-2,5-dione | ||
| Canonical SMILES | O=C(C(C)=C1O)[C@@H]2O[C@@H]2C1=O | ||
| Formula | C7H6O4 | M.Wt | 154.12 |
| Solubility | DMF: soluble,DMSO: 10 mg/ml,Ethanol: soluble,Methanol: soluble,Water: 5 mg/ml | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 6.4885 mL | 32.4423 mL | 64.8845 mL |
| 5 mM | 1.2977 mL | 6.4885 mL | 12.9769 mL |
| 10 mM | 0.6488 mL | 3.2442 mL | 6.4885 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 37 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *